Review of non-clinical risk models to aid prevention of breast cancer

被引:0
|
作者
Kawthar Al-Ajmi
Artitaya Lophatananon
Martin Yuille
William Ollier
Kenneth R. Muir
机构
[1] The University of Manchester,Division of Population Health, Health Services Research and Primary Care, Faculty of Biology, Medicine and Health, Centre for Epidemiology
来源
Cancer Causes & Control | 2018年 / 29卷
关键词
Assessment risk tool; Calibration; Discrimination; Risk factors; Risk prediction; Concordance and E/O statistics;
D O I
暂无
中图分类号
学科分类号
摘要
A disease risk model is a statistical method which assesses the probability that an individual will develop one or more diseases within a stated period of time. Such models take into account the presence or absence of specific epidemiological risk factors associated with the disease and thereby potentially identify individuals at higher risk. Such models are currently used clinically to identify people at higher risk, including identifying women who are at increased risk of developing breast cancer. Many genetic and non-genetic breast cancer risk models have been developed previously. We have evaluated existing non-genetic/non-clinical models for breast cancer that incorporate modifiable risk factors. This review focuses on risk models that can be used by women themselves in the community in the absence of clinical risk factors characterization. The inclusion of modifiable factors in these models means that they can be used to improve primary prevention and health education pertinent for breast cancer. Literature searches were conducted using PubMed, ScienceDirect and the Cochrane Database of Systematic Reviews. Fourteen studies were eligible for review with sample sizes ranging from 654 to 248,407 participants. All models reviewed had acceptable calibration measures, with expected/observed (E/O) ratios ranging from 0.79 to 1.17. However, discrimination measures were variable across studies with concordance statistics (C-statistics) ranging from 0.56 to 0.89. We conclude that breast cancer risk models that include modifiable risk factors have been well calibrated but have less ability to discriminate. The latter may be a consequence of the omission of some significant risk factors in the models or from applying models to studies with limited sample sizes. More importantly, external validation is missing for most of the models. Generalization across models is also problematic as some variables may not be considered applicable to some populations and each model performance is conditioned by particular population characteristics. In conclusion, it is clear that there is still a need to develop a more reliable model for estimating breast cancer risk which has a good calibration, ability to accurately discriminate high risk and with better generalizability across populations.
引用
收藏
页码:967 / 986
页数:19
相关论文
共 50 条
  • [41] Docetaxel-trastuzumab stealth immunoliposome: design and non-clinical study in HER2+and HER2-breast cancer models
    Fanciullino, Raphaelle R.
    Brunel, Jean-Michel
    Correard, Florian
    Giacometti, Sarah
    Ciccolini, Joseph
    CANCER RESEARCH, 2015, 75
  • [42] IEN in clinical trial models to evaluate new drugs for breast cancer prevention
    Fabian, CJ
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (11) : 1369S - 1370S
  • [43] Non-clinical patient-derived models for co-clinical trial
    Koga, Yoshikatsu
    ANNALS OF ONCOLOGY, 2022, 33 : S435 - S435
  • [44] The role of curcumin/curcuminoids during gastric cancer chemotherapy: A systematic review of non-clinical study
    Najafi, Masoud
    Mortezaee, Keywan
    Rahimifard, Mahban
    Farhood, Bagher
    Haghi-Aminjan, Hamed
    LIFE SCIENCES, 2020, 257
  • [45] Polygenic risk for schizophrenia and schizotypal traits in non-clinical subjects
    Nenadic, Igor
    Meller, Tina
    Schmitt, Simon
    Stein, Frederike
    Brosch, Katharina
    Mosebach, Johannes
    Ettinger, Ulrich
    Grant, Phillip
    Meinert, Susanne
    Opel, Nils
    Lemke, Hannah
    Fingas, Stella
    Foerster, Katharina
    Hahn, Tim
    Jansen, Andreas
    Andlauer, Till F. M.
    Forstner, Andreas J.
    Heilmann-Heimbach, Stefanie
    Hall, Alisha S. M.
    Awasthi, Swapnil
    Ripke, Stephan
    Witt, Stephanie H.
    Rietschel, Marcella
    Mueller-Myhsok, Bertram
    Noethen, Markus M.
    Dannlowski, Udo
    Krug, Axel
    Streit, Fabian
    Kircher, Tilo
    PSYCHOLOGICAL MEDICINE, 2022, 52 (06) : 1069 - 1079
  • [46] Risk determination and prevention of breast cancer
    Howell, Anthony
    Anderson, Annie S.
    Clarke, Robert B.
    Duffy, Stephen W.
    Evans, D. Gareth
    Garcia-Closas, Montserat
    Gescher, Andy J.
    Key, Timothy J.
    Saxton, John M.
    Harvie, Michelle N.
    BREAST CANCER RESEARCH, 2014, 16 (05):
  • [47] Breast cancer risk: Screening and prevention
    Crowe, JP
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1998, 187 (04) : 454 - 455
  • [48] Risk determination and prevention of breast cancer
    Anthony Howell
    Annie S Anderson
    Robert B Clarke
    Stephen W Duffy
    D Gareth Evans
    Montserat Garcia-Closas
    Andy J Gescher
    Timothy J Key
    John M Saxton
    Michelle N Harvie
    Breast Cancer Research, 16
  • [49] Non-clinical strategies to address QT liability and proarrhythmic risk
    Pollard, C.
    Valentin, J-P
    Hammond, T.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 : 8 - 8
  • [50] Breast cancer risk and prevention in 2024: An overview from the Breast Cancer UK - Breast Cancer Prevention Conference
    Stordal, Britta
    Harvie, Michelle
    Antoniou, Michael N.
    Bellingham, Michelle
    Chan, Doris S. M.
    Darbre, Philippa
    Karlsson, Oskar
    Kortenkamp, Andreas
    Magee, Pamela
    Mandriota, Stefano
    Silva, Elisabete
    Turner, James E.
    Vandenberg, Laura N.
    Evans, D. Gareth
    CANCER MEDICINE, 2024, 13 (18):